title: Transcranial magnetic stimulation for major depressive disorder: a pragmatic approach to implementing TMS in a clinical practice.
abstract: Another option for managing major depressive disorder (MDD) became available in October 2008 with the Food and Drug Administration's (FDA) market clearance of NeuroStar TMS (transcranial magnetic stimulation) Therapy System. A panel of psychiatrists who have been treating patients with NeuroStar TMS Therapy in their clinics assembled for a virtual roundtable discussion regarding their experiences. In this supplement, the panel addresses the following issues: the FDA-cleared indication for use of NeuroStar TMS Therapy; logistic and staffing considerations in the outpatient setting; selecting the right patient for TMS Therapy; talking with patients and family about TMS Therapy. To give the overview a meaningful context, each panelist shares a personal account of a patient case, describing the treatment course and outcomes achieved with TMS Therapy.
authors.affiliation: SunPointe Health, State College, PA, USA.
authors.forename: Timothy
authors.initials: T
authors.lastname: Derstine
authors.forename: Karl
authors.initials: K
authors.lastname: Lanocha
authors.forename: Carl
authors.initials: C
authors.lastname: Wahlstrom
authors.forename: Todd M
authors.initials: TM
authors.lastname: Hutton
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011575:Psychoanalytic Therapy; D050781:Transcranial Magnetic Stimulation / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents